1-Fluorochromeno[2,3-c]pyridin-5-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-Fluorochromeno[2,3-c]pyridin-5-one
• 英文别名: 1-fluorochromeno[2,3-c]pyridin-5-one
• 化学式: C₁₂H₆FNO₂
• 分子量: 215.18
• InChiKey: FGAJXYRFQWMPJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
  申请人：CERULEAN PHARMA INC.

  公开号：US20130203700A1

  公开（公告）日：2013-08-08

  The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

  本发明涉及一种新型治疗环糊精含聚合物组成物，其设计为小分子治疗药物的载体，并且包括其制药组合物。这些含环糊精的聚合物可以提高药物的稳定性和溶解度，并在体内使用时降低小分子治疗药物的毒性。此外，通过从多种连接基团和靶向配体中进行选择，这些聚合物提供了治疗剂的可控释放方法。本发明还涉及使用上述治疗组合物治疗受试者的方法。此外，本发明还涉及制药业务的方法，包括制造，许可或分发包含或涉及上述聚合物化合物的试剂盒。
• [EN] AMINO-OXAZINE AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE<br/>[FR] COMPOSÉS D'AMINO-OXAZINE ET D'AMINO-DIHYDROTHIAZINE JOUANT LE RÔLE DE MODULATEURS DE BÊTA-SÉCRÉTASE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2014078314A1

  公开（公告）日：2014-05-22

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, L, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.